News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
Aakash Desai: Roche received Breakthrough Device Designation from the FDA for the VENTANA TROP2 RxDx Device
roche.com
Apr 30, 2025, 07:43

Aakash Desai: Roche received Breakthrough Device Designation from the FDA for the VENTANA TROP2 RxDx Device

Aakash Desai, Associate Director of Phase 1 and Precision Oncology Program at UAB O’Neal Comprehensive Cancer Center, shared a post on LinkedIn:

“Exciting news in precision oncology:

Roche has received Breakthrough Device Designation from the FDA for the VENTANA TROP2 (EPR20043) RxDx Device—the first AI-powered companion diagnostic in non-small cell lung cancer (NSCLC).

What makes it groundbreaking:

  • Combines AI-driven image analysis with digital pathology.
  • Offers a new level of diagnostic precision beyond manual methods.
  • Enables more tailored treatment decisions in NSCLC.

This milestone underscores the power of AI + diagnostics to transform cancer care by delivering more personalized, and efficient solutions. How can we scale and make this more clinically applicable is the next?”

Aakash Desai: Roche received Breakthrough Device Designation from the FDA for the VENTANA TROP2 RxDx Device

More posts featuring Aakash Desai.

Aakash Desai AI + diagnostics cancer cancer care Digital pathology FDA fight against cancer Global fight against cancer non small cell lung cancer NSCLC OncoDaily Oncology Precision Oncology Roche RxDx Device VENTANA TROP2
Special Coverage
Blog
Apr 30, 2025, 11:20
Sylvain Delaunay: Exciting Postdoctoral Researcher opportunity at Cancer Research UK Manchester Institute
Blog
Apr 30, 2025, 11:15
Istvan Petak: The same vision of AACR, "cancer research saves lives"
Science
Apr 30, 2025, 11:05
Michael Lemma: Our paper on the very unique psychosocial support group in Eastern Ethiopia has been published
Blog
Apr 30, 2025, 11:02
Sitna Ali Mwanzi Highlights Cancer Patient Navigation Work in Kenya
Blog
Apr 30, 2025, 10:53
Amol Akhade: Aumolertinib and Chemotherapy, A New Challenger to Osimertinib?
Science
Apr 30, 2025, 10:42
George Vlachogiannis: Modified Glasgow Prognostic Score can reliably predict osteoporosis risk in elderly cancer patients
Blog
Apr 30, 2025, 10:36
Douglas Flora: Don’t Let AI Make You Irrelevant - Start Preparing Today
Science
Apr 30, 2025, 10:26
Herbert Loong: Promising data on D3S-001 at AACR25
Blog
Apr 30, 2025, 10:19
Eric Singhi: Very excited to join this year’s LUNGevity Foundation HOPE Summit
Blog
Apr 30, 2025, 10:11
Patricia M. LoRusso and Robin Zon co-moderated AACR - ASCO Joint Session at AACR25
Blog
Apr 30, 2025, 10:10
Giuseppe Lombardi: Registration is open for the International Congress in Neuro-Oncology in Padova
Science
Apr 30, 2025, 10:10
Maryam Lustberg: Editorial on the unmets breast cancer survivors and menopause